Terms: = Leukemia AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Prognosis
11 results:
1. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].
Wang Y; Gao QY; Wang H; Zhang D; Gao Y; Miao YD; Zhai XH; Hu XX; Rui XL; Zhang WH
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):800-804. PubMed ID: 38049330
[No Abstract] [Full Text] [Related]
3. bcma CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract] [Full Text] [Related]
4. A phase I study of anti-bcma CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
[TBL] [Abstract] [Full Text] [Related]
5. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
Jasiński M; Basak GW; Jedrzejczak WW
Front Immunol; 2021; 12():632937. PubMed ID: 33717171
[TBL] [Abstract] [Full Text] [Related]
6. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract] [Full Text] [Related]
7. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
[TBL] [Abstract] [Full Text] [Related]
9. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance.
Venturini L; Daidone MG; Motta R; Cimino-Reale G; Hoare SF; Gronchi A; Folini M; Keith WN; Zaffaroni N
Neuro Oncol; 2012 Jun; 14(6):736-44. PubMed ID: 22516689
[TBL] [Abstract] [Full Text] [Related]
10. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract] [Full Text] [Related]
11. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract] [Full Text] [Related]